AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) was the recipient of some unusual options trading on Thursday. Stock investors purchased 1,049 put options on the stock. This represents an increase of 854% compared to the typical daily volume of 110 put options.
Several hedge funds and other institutional investors have recently made changes to their positions in AMAG. First Trust Advisors LP purchased a new position in shares of AMAG Pharmaceuticals in the third quarter valued at $735,000. Aperio Group LLC purchased a new position in shares of AMAG Pharmaceuticals in the third quarter valued at $198,000. Crossmark Global Holdings Inc. purchased a new position in shares of AMAG Pharmaceuticals in the third quarter valued at $244,000. BNP Paribas Arbitrage SA grew its position in shares of AMAG Pharmaceuticals by 8.2% in the third quarter. BNP Paribas Arbitrage SA now owns 81,231 shares of the specialty pharmaceutical company’s stock valued at $1,499,000 after purchasing an additional 6,147 shares in the last quarter. Finally, Sei Investments Co. grew its position in shares of AMAG Pharmaceuticals by 46.3% in the third quarter. Sei Investments Co. now owns 15,795 shares of the specialty pharmaceutical company’s stock valued at $291,000 after purchasing an additional 4,996 shares in the last quarter.
Several brokerages have issued reports on AMAG. BidaskClub lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, March 10th. Cantor Fitzgerald restated a “hold” rating and issued a $17.00 target price on shares of AMAG Pharmaceuticals in a research note on Tuesday, February 27th. B. Riley boosted their target price on AMAG Pharmaceuticals from $16.00 to $23.00 and gave the company a “neutral” rating in a research note on Wednesday, March 14th. Jefferies Group lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their target price for the company from $21.00 to $20.00 in a research note on Monday, March 5th. Finally, ValuEngine upgraded AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. Twelve equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $23.91.
AMAG Pharmaceuticals (NASDAQ:AMAG) opened at $19.60 on Friday. The firm has a market capitalization of $669.85, a price-to-earnings ratio of -3.46 and a beta of 0.28. AMAG Pharmaceuticals has a 52-week low of $11.93 and a 52-week high of $24.85. The company has a debt-to-equity ratio of 0.93, a current ratio of 1.74 and a quick ratio of 1.60.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.68. The company had revenue of $158.30 million during the quarter, compared to analysts’ expectations of $158.84 million. AMAG Pharmaceuticals had a positive return on equity of 0.96% and a negative net margin of 32.66%. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.31) earnings per share. analysts anticipate that AMAG Pharmaceuticals will post -3.25 EPS for the current year.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.